Clinical trial

Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD

NCT02221622

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2014-08-01

PhasePHASE1

Study timeline

Study start (unknown)2014-08-01Date precision: month

Registry last updated2019-07-05

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Mild Cognitive Impairmentunresolved

Alzheimer Diseaseunresolved

Interventions

Allopregnanolone injection (intravenous solution)DRUG

Placebo injection (intravenous solution)DRUG

Sponsors & collaborators

University of Southern Californialead sponsor

National Institute on Aging (NIA)collaborator

Mapped research locations

Los AngelesCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02221622 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.